Patients with intestinal polyps have lower risk of dying from cancer

Published on August 28, 2014 at 5:46 AM · No Comments

Patients with intestinal polyps have a lower risk of dying from cancer than previously thought, according to Norwegian researchers.

This group of patients may therefore need less frequent colonoscopic surveillance than what is common today. As a potential concequence, the researchers argue, health service resources may be diverted to other, patient groups.

The findings were released today in The New England Journal of Medicine (NEJM).

World's largest
----------------

The Norwegian study is the world's largest of its kind, and involved following up patients over a longer time span than has previously been done.

Researchers estimated the risk of colorectal mortality in more than 40,000 Norwegian patients who had undergone removal of polyps. They were then monitored for up to 19 years. All deaths were recorded.

No higher risk
--------------

"The results indicate that patients who previously had colorectal polyps removed, do not have a higher risk of death caused by colorectal cancer than the general Norwegian population", says co-author Dr. Mette Kalager.

A public health problem
--------------------------

Colorectal cancer is one of the most common cancers in Norway and poses a significant public health problem. More than 3,600 new cases are registered in the country each year and the incidence has increased rapidly in recent decades.

According to current national guidelines in Norway, patients who previously have removed polyps are recommended colonoscopic screening. This is recommended because of the assumption that these patients have an increased risk of colorectal cancer.

The number of patients waiting in line for this kind screening is rapidly growing, however, eventually putting a strain on hospital resources.

Say Dr. Magnus Løberg, primary author and research team member:

"Patients with polyps may not need such a frequent colonoscopic surveillance as we have today. The resources could rather be used on symptomatic patients".

The members of the research team are affiliated with Oslo University Hospital and the University of Oslo.

Posted in: Medical Condition News | Healthcare News

Tags: , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients